CUSTIRSEN IN COMBINATION WITH DOCETAXEL AND PREDNISONE FOR PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (SYNERGY TRIAL): A PHASE 3, MULTICENTRE, OPEN-LABEL, RANDOMISED TRIAL ArticleChi K.N., Gleave M., Higano C.S., Blumenstein B., Ferrero J.M., Reeves J., Feyerabend S., Stenzl A., Gravis G., Merseburger A.S., Bergman A.M., Mukherjee S.D., Zalewski P., Saad F., Jacobs C., De Bono J.S.The Lancet Oncology. Том 18. 2017. С. 473-485
